Incyte announces 52-week results from povorcitinib trial

Incyte announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib, an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa, or HS. These data were presented as an oral presentation at the 12th Conference of the European Hidradenitis Suppurativa Foundation, held from February 8-10, 2023, in Florence, Italy. The study previously met its primary endpoint, demonstrating that at Week 16 – the double-blind, placebo-controlled portion of the study – patients receiving povorcitinib once daily, or QD, had significantly greater decreases from baseline in Abscess and Inflammatory Nodule, or AN, count versus placebo. New results at Week 52, which include the 36-week open-label extension period during which all patients received povorcitinib 75 mg once daily, show that average efficacy was sustained for all treatment arms following the switch to povorcitinib 75 mg QD. Importantly, povorcitinib also demonstrated durable efficacy at Week 52 in high-threshold outcomes, as evidenced by 22%-29% of patients achieving HS Clinical Response 100, which is defined as a 100% reduction from baseline in total AN count with no increase from baseline in abscess or draining tunnel count. Povorcitinib was generally well tolerated and the safety profile was consistent with previously-reported data. The most common treatment-emergent adverse events, or TEAEs, at Week 52 were COVID-19, acne, upper respiratory tract infection, headache, nasopharyngitis, urinary tract infection and increased blood creatine kinase, or CK. In total, six patients experienced a TEAE that led to treatment discontinuation. No fatal TEAEs were observed.